Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year distribution agreement with Xenith, LLC, based in Dubai, UAE, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator, the BoneScalpel(TM) Ultrasonic Bone Cutter, and the SonicOne® Ultrasonic Wound Debrider. The agreement provides Xenith with the rights to sell exclusively in the UAE and other select markets and includes minimum purchase requirements.
Xenith, well known in the Middle East as an aggressive competitor, has built a solid reputation as a distributor of state-of-the-art medical devices and capital equipment, with special emphasis on surgery and oncology.
The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
"Misonix is pleased to add Xenith to our rapidly expanding roster of Middle Eastern specialty distributors," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Xenith's commitments to quality and service to its clinical customers is well recognized in the UAE and we are pleased that they will be distributing three of our products through their well established distribution network."
Protein discovery offers insights into bone health and potential treatments for osteoporosis